Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1708)	10/13/2006 3:21:42 PM
From: tuck	Read Replies (1) \| Respond to of 1826

Well, that's the lowest number I've seen for peak sales. Not that I've seen many. A Yahoo had $100 million from an undisclosed source. Amgen's Palifermin, in PIII for solid tumor regimens, and already approved for oral mucositis arising from hematological malignancies, was projected to have peak sales of $750 to $1 billion. That's an old number from a couple of years ago. I don't recall seeing a number for actual sales of Palifermin. So something has changed or there is a disconnect I'm missing. The other aspect of the economics of Saforis for MOGN is that I believe they'd owe the licensor a milestone of approximately ~$30 million if approved. So I don't see them continuing the program, either. Obviously, Merrill's support is helping today, so I ain't complaining. Ward, I agree with your analysis, but the strong Dacogen launch has been news for several weeks. Has anyone actually seen scrips? Cheers, Tuck